在急性前兆细胞白血病中RARα融合基因的进展

Ao Zhang1, Shaowei Qiu1

  • 1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China; Tianjin Institutes of Health Science, Tianjin, China.

PubMed
概括

急性促细胞白血病 (APL) 是由PML-RARα融合基因驱动的. 虽然全转网红酸 (ATRA) 和三氧化 (ATO) 改善了治疗,但耐药性和变异基因对APL预后构成了挑战.